Surfing the NASH Tsunami shares Dr. Marcelo Kugelmas’s portion of the Madrigal Pharmaceuticals presentation at NAFLD, which covers NAFLD patient screening and diagnostics along with NASH patient management. After this, he answers questions from Roger Green, who then interviews Dr. Naim Alkhouri on disease prevalence and strategies for bringing patient to be tested.
Surfing the NASH Tsunami shares Dr. Mazen Noureddin’s portion of the Madrigal Pharmaceuticals presentation at NAFLD, which covers NAFLD pathophysiology and NASH epidemiology. After this, he answers questions from Roger Green.
Jörn Schattenberg, Louise Campbell and Roger Green wrap up the discussion of NASH drug development in 2022 by citing their reasons for optimism, ranging from what researchers have proven already about safety and efficacy to the likelihood that combination therapy will eventually become the core therapeutic strategy and the emerging importance of quality of life measures.
Stephen Harrison, Jörn Schattenberg, Louise Campbell and Roger Green all discuss the role that combination NASH drugs and greater population diversity in clinical trials will strengthen NASH drug development.
Stephen Harrison leads a review of drug development and where we are in the NASH pipeline as Jörn Schattenberg, Louise Campbell and Roger Green lend their own perspectives and ask questions
Roger Green interviews physician, author, and entrepreneur Marcus Ranney about his experiences, the ability of data and digital health to empower health seekers, and the foundational vision that led him to form Human Edge and develop the Mito app.
On May 6 and 7, over 100 NAFLD stakeholders convened in Barcelona and online for the inaugural Innovations in NAFLD Care 2022 conference (#INCBCN.)
On May 6 and 7, over 100 NAFLD stakeholders convened in Barcelona and online for the inaugural Innovations in NAFLD Care 2022 conference (#INCBCN.)
Innovations in NAFLD Care conferece co-chair Jeff Lazarus joins Roger Green, Louise Campbell and Jörn Schattenberg to review conference goals and ask whether the agenda and participants put forth a vision of an integrated NAFLD Care pathway. This conversation centers around areas for controversy, including data-driven patient empowerment and what the proper name for this disease should be.
Innovations in NAFLD Care conferece co-chair Jeff Lazarus joins Roger Green, Louise Campbell and Jörn Schattenberg to review conference goals and ask whether the agenda and participants put forth a vision of an integrated NAFLD Care pathway.
